EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
NEW YORK, March 16, 2017 -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in the following investor conference:
- Oppenheimer 27th Annual Healthcare Conference on March 21, 2017 at 3:55 p.m. Eastern Time
Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.
CONTACT: For more information about Intercept Pharmaceuticals, please contact: Intercept Pharmaceuticals: Mark Vignola +1-646-747-1000 [email protected] Media inquiries: [email protected] Investor inquiries: [email protected]
